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Ferric pyrophosphate citrate (FPC) is a water-soluble iron
salt administered via dialysate to supply iron directly to
transferrin. The PRIME study tested whether treatment with
FPC could reduce prescribed erythropoiesis-stimulating
agent (ESA) use and maintain hemoglobin in hemodialysis
patients. This 9-month, randomized, placebo-controlled,
double-blind, multicenter clinical study included 103 patients
undergoing hemodialysis 3–4 times weekly. The FPC group
received dialysate containing 2 μmol/l of iron. The placebo
group received standard dialysate. A blinded central anemia
management group facilitated ESA dose adjustments.
Intravenous iron was administered according to the
approved indication when ferritin levels fell below 200 μg/l.
The primary end point was the percentage change from
baseline in prescribed ESA dose at end of treatment.
Secondary end points included intravenous iron use and
safety. At the end of treatment, there was a significant 35%
reduction in prescribed ESA dose in FPC-treated patients
compared with placebo. The FPC patients used 51% less
intravenous iron than placebo. Adverse and serious adverse
events were similar in both groups. Thus, FPC delivered via
dialysate significantly reduces the prescribed ESA dose and
the amount of intravenous iron needed to maintain
hemoglobin in chronic hemodialysis patients.
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Anemia is an inevitable complication in patients with
chronic kidney disease who receive maintenance hemo-
dialysis (CKD 5HD). This is primarily because of loss of renal
erythropoietin production, chronic inflammation, and
increased blood losses related to uremia and hemodialysis.
The result is an iron loss of ∼ 5–7mg per dialysis session.1,2
Although erythropoietin deficiency and inflammatory suppres-
sion of erythropoiesis can be partly counteracted by
erythropoiesis-stimulating agents (ESAs), increased erythroid
iron requirements because of ESAs, together with ongoing
blood losses, exceed the amount of iron that can be provided
from adequate marrow iron stores.3 Furthermore, chronic
inflammation suppresses the iron supply that is available
from stores by stimulating hepatic production of hepcidin.3,4
Hepcidin prevents efflux of iron from stores into plasma.5 Iron
is then retained within reticuloendothelial (RE) macrophages
in bone marrow, liver, and spleen. Plasma transferrin
saturation (TSAT) falls, making iron inaccessible for red blood
cell production.6 Intravenous (i.v.) iron is commonly adminis-
tered in hemodialysis patients to replace dialysis-related blood
losses and to overcome inflammatory sequestration of iron.
The i.v. iron products comprise ferric hydroxide cores
within a carbohydrate shell and require uptake and processing
by RE macrophages. With concurrent inflammation, a
considerable proportion of iron derived from these iron
carbohydrate complexes is sequestered within macrophages
and is not readily available for transport to erythroid marrow
for use in hemoglobin (Hgb) synthesis.7 Although approved
and indicated for treatment of iron deficiency anemia, i.v.
iron products are commonly used as a ‘maintenance’ therapy
to replace ongoing iron losses in hemodialysis patients. As a
result, serum ferritin levels have increased from ∼ 400 to
800 μg/l over the past decade in the United States,8 leading to
concerns about iron overload and consequent inflammation,
oxidative stress, endothelial dysfunction, cardiovascular
disease, immune dysfunction, and the risk of bacterial
infections.9
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Ferric pyrophosphate citrate (FPC) was first used to deliver
iron via dialysate in 1999 and allowed maintenance of
Hgb and iron balance while reducing the need for i.v. iron
by ~ 80%.10 Rockwell Medical licensed FPC in 2002 and
conducted pharmacology–toxicology studies and a phase
1–3 clinical program. FPC (Triferic) was approved by the US
Food and Drug Administration (FDA) in January 2015 as the
first iron product indicated to maintain Hgb in adult CKD
5HD patients.
FPC is added to liquid bicarbonate concentrate at the
clinic. The bicarbonate concentrate with FPC subsequently
mixes with acid concentrate and water in the hemodialysis
machine to generate dialysate. FPC crosses the dialyzer
membrane, enters the blood, donates its iron directly to
transferrin, and is rapidly cleared from circulation. This
provides for optimal iron utilization for erythropoiesis and
avoids iron sequestration within RE macrophages.10,11
The PRIME (Physiological Replenishment Iron Mainte-
nance Equivalency) study tested the hypothesis that admin-
istration of FPC via dialysate during hemodialysis sessions
would reduce prescribed ESA use and maintain Hgb in the
recommended range in CKD 5HD patients.
RESULTS
Study population
A total of 108 patients were randomized; 52 received FPC, 51
received placebo, and 5 discontinued before receiving study
drug. Baseline demographic and clinical characteristics,
including amount of prescribed ESA per week at baseline
and amount of i.v. iron administered ⩽ 6 weeks before study
start, were similar between groups (Table 1). Most patients
were male (61.2%) and white (61.2%); mean age was 59 years
(range, 25–93 years).
In all, 75% of randomized patients completed the study; 11
patients in each group discontinued prematurely. Reasons for
discontinuation were similar between groups (Figure 1).
Two patients randomized to placebo received one dose of
FPC in error. These patients were included in the placebo group
in the efficacy analyses (modified intent-to-treat population)
and in the FPC group in the safety analyses (Figure 1). All
patients, including those who prematurely discontinued from
the study, were included in the efficacy and safety analyses.
Efficacy outcomes
FPC delivered via dialysate reliably delivered iron to patients
while significantly reducing prescribed ESA by 35% relative to
placebo. Mean serum iron level during a single dialysis
treatment increased in the FPC group from 63.5 μg/dl before
dialysis to 215.0 μg/dl after dialysis (95% confidence interval
(CI), 197.1–233.5) but did not change significantly in the
placebo group (Figure 2a). The Hgb concentration was
maintained at baseline levels in both groups. At the end of
treatment (EoT), the ESA dose was not significantly changed
from baseline in the FPC group (+4.9%; 95% CI, −19.1 to
28.8) but had increased 39.8% (95% CI, 15.7–64.0) from
baseline in the placebo group (Figure 3a). The least squares
mean difference (FPC–placebo) in the prescribed ESA dose
was 35% (95% CI, −69.1 to −0.8; P= 0.045). A prespecified
analysis of the B20% ESA-hyporesponsive patients in each
group (baseline ESA 413,000 units/week) showed a 74.4%
reduction in the prescribed ESA dose in the FPC group (not
statistically significant because of small sample size).
In each group, 11 patients did not complete the 9-month
study. Analysis of percentage change from baseline in prescribed
ESA showed that the effect of FPC in these patients was similar
to that in the entire study population (mean (s.d.): FPC,
+27.5% (56.3%); placebo, +60.0% (98.7%)).
Fewer FPC-treated patients (11/52, 21.2%) than placebo-
treated patients (20/51, 39.2%) required i.v. iron supple-
mentation. Overall, the FPC group required 51% less i.v. iron
supplementation (mean (s.d.), 7.9 (27.2) mg/4 weeks vs.
15.9 (35.6) mg/4 weeks; P= 0.044; Figure 3b). Patients who
required supplemental iron received similar amounts (mean,
37.3 mg/4 weeks for FPC vs. 40.6 mg/4 weeks for placebo).
Mean TSAT before and after dialysis increased from 23.9%
(95% CI, 20.9–26.9%) to 74.7% (95% CI, 69.1–80.3%) at
Table 1 |Baseline demographics and renal history
Characteristic FPC, n=54a Placebo, n=49a
Age (years), mean (s.d.) 59.4 (12.4) 58.5 (13.9)
Male sex 31 (57.4%) 32 (65.3%)
Race
White 31 (57.4%) 32 (65.3%)
Other 23 (42.6%) 17 (34.7%)
Posthemodialysis weight (kg), mean (s.d.) 85.2 (17.4) 83.5 (17.6)
Time since first hemodialysis (mo),
mean (s.d.)
47.6 (49.2) 44.9 (63.7)
Prescribed ESA, mean (s.d.)
Epoetin (units/week) 9625 (5644) 9168 (5285)
Darbepoetin (μg/week) — 18.8 (8.8)
Intravenous iron in previous 6 weeks
(mg), mean (s.d.)
102.1 (128.6) 96.4 (111.9)
Serum iron (μg/dl), mean (s.d.) 66.6 (16.8) 73.2 (23.1)
Serum transferrin (g/l), mean (s.d.) 1.8 (0.3) 1.8 (0.3)
Serum TSAT (%), mean (s.d.) 26.7 (7.1) 28.5 (7.6)
Serum ferritin (μg/l), mean (s.d.) 625.8 (192.7) 599.5 (226.5)
TIBC (μg/dl), mean (s.d.) 226.9 (30.6) 231.2 (38.4)
UIBC (μg/dl), mean (s.d.) 160.4 (31.5) 158.0 (31.5)
Relevant medical history
Diabetes 34 (63.0%) 36 (73.5%)
Cardiovascular disease
Congestive heart failure 20 (37.0%) 23 (46.9%)
Coronary artery disease 14 (25.9%) 26 (53.1%)
Myocardial infarction 6 (11.1%) 7 (14.3%)
Angina pectoris 4 (7.4%) 4 (8.2%)
Atrial fibrillation 3 (5.6%) 4 (8.2%)
Bradycardia 3 (5.6%) 3 (6.1%)
Abbreviations: ESA, erythropoiesis-stimulating agent; FPC, ferric pyrophosphate
citrate; TIBC, total iron binding capacity; TSAT, transferrin saturation; UIBC,
unsaturated iron binding capacity.
aTwo patients who were randomized to the placebo group and who incorrectly
received a dose of FPC in error were included in the FPC group in the safety
analyses (safety population, FPC, n=54; placebo, n=49) but were analyzed in the
placebo group in the efficacy analyses (modified intent-to-treat population, FPC,
n=52; placebo, n=51).
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EoT in the FPC group but did not change significantly in the
placebo group (22.6–25.0%; Figure 2a). Mean serum iron
levels increased from before dialysis to after dialysis in the
FPC group. The mean incremental change in serum iron from
before to after dialysis during the study was 102.3 μg/dl (95%
CI, 93.8–110.8) and 2.9 μg/dl (95% CI, 0.4–5.4) in the FPC
and placebo groups, respectively.
Serum iron results were consistent with previous studies
showing that iron is rapidly cleared in FPC-treated patients
and returns to baseline levels by the next dialysis session.10
Predialysis serum iron levels were not significantly different
from those of placebo during the study (Figure 2b).
Postdialysis serum iron values were similar at each observa-
tion over the study in the FPC group.
Reticulocyte hemoglobin levels were relatively maintained
from baseline through EoT in the FPC group but showed
a steady decline during the study in the placebo group
(Figure 4).
At EoT, mean predialysis serum ferritin level was not signif-
icantly changed from baseline in the FPC group (−61.9 μg/l;
95% CI, −128.7 to 4.9) but had declined in the placebo group
(−156.0 μg/l; 95% CI, −233.2 to −78.8; Figure 3c). The
difference between groups (94.0 μg/l; 95% CI, −10.6 to 198.6)
was not statistically significant at EoT (P= 0.077).
Measurement of markers of inflammation and oxidative
stress over the study revealed no statistically significant
differences between groups in predialysis interleukin-6 or
malondialdehyde (Figure 5). Mean C-reactive protein levels
were similar between groups at baseline (FPC, 92.0 nmol/l;
placebo, 91.4 nmol/l). At EoT, mean C-reactive protein levels
were 90.3 nmol/l and 128.2 nmol/l in the FPC and placebo
groups, respectively; the difference between groups was not
statistically significant (−37.9 nmol/l; 95% CI, − 101.3 to 25.6).
Adverse events
Treatment-related treatment-emergent adverse events
(TEAEs) were reported in 7.4% (4/54) and 6.1% (3/49) of
the FPC-treated and placebo-treated patients, respectively.
Serious TEAEs (FPC, 33.3%; placebo, 40.8%) and TEAEs
resulting in study discontinuation (FPC, 7.4%; placebo, 2.0%)
were assessed by investigators as unrelated to the study
drug. Deaths (FPC, 2; placebo, 3) occurred only during the
interdialytic interval and were not considered related to study
drug.
Enrollment Assessed for eligibility (n = 298)
Randomized (n = 108)
Allocated to placebo (n = 54)
• Received placebo (n = 51)
• Did not receive placebo (n = 3)
Adverse event (n = 1)
Protocol violation (n = 2)
Allocated to FPC (n = 54)
Lost to follow-up (n = 0)
Discontinued FPC (n = 11)
• Adverse event (n = 3)
Death (n = 2)
• Withdrew consent (n = 4)
• Investigator decision (n = 2)
• Protocol violation (n = 1)
• 2 placebo-treated patients received
 1 dose of FPC in error
• Other (n = 1)
Efficacy (mITT, n = 52) Efficacy (mITT, n = 51)
Safety (n = 54) Safety (n = 49)
Lost to follow-up (n = 0)
Discontinued placebo (n = 11)
• Adverse event (n = 3)
Death (n = 3)
• Withdrew consent (n = 4)
• Investigator decision (n = 0)
• Protocol violation (n = 1)
• Other (n = 3)
• Received FPC (n = 52)
• Did not receive FPC (n = 2)
 Protocol deviation - ESA dosing
 (n = 2)
Allocation
Follow-up
Analysis
Excluded (n = 190)
• Did not meet inclusion criteria (n = 162)
• Declined to participate (n = 6)
• Other reasons (n = 22)
Figure 1 |Patient disposition—CONSORT diagram. ESA, erythropoiesis-stimulating agent; FPC, ferric pyrophosphate citrate; mITT, modified
intent-to-treat.
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Cardiac events were reported in similar percentages of
patients (FPC, 25.9%; placebo, 26.5%; Table 2). Hemo-
dialysis-induced symptoms (22.2% vs. 12.2%) and cough
(22.2% vs. 6.1%) were reported more frequently in the FPC
group (Table 3), occurred at various times during the treatment
period, and were not attributed to study drug. Bradycardia was
reported more frequently in the FPC group (13.0% vs. 4.1%),
was transient, generally occurred with intradialytic hypotension,
and was not considered related to study drug.
The incidence of intradialytic hypotension was similar in
the FPC and placebo groups, occurring during 4.7% and 5.5%
of dialysis sessions, respectively (see Supplementary Table S1
online). The severity of intradialytic hypotension was also
similar between the FPC and placebo groups: intradialytic
hypotension episodes meeting adverse event reporting criteria
and requiring intervention occurred in 2.0% and 2.2% of
dialysis sessions, respectively (see Supplementary Tables S1,
S2 and S3 online). Two patients in each group developed
procedural hypotension that was considered possibly related
to treatment. No hypersensitivity reactions to study drug were
reported. Five patients (FPC, 2; placebo, 3) received blood
transfusions.
DISCUSSION
FPC is a new FDA-approved iron replacement product that
significantly reduces ESA requirements while maintaining
Hgb in hemodialysis patients. The unique mode of action of
FPC enables effective erythropoiesis by donating iron directly
to transferrin, thereby bypassing the hepcidin block to iron
efflux from the RE system that leads to iron sequestration and
a functional iron deficiency in uremic patients.
The objective of this controlled study was to demonstrate
that FPC can reduce the prescribed ESA requirement when
ESA doses are administered in accordance with a protocol-
specified ESA algorithm. FPC-treated patients required 35%
less ESA than placebo-treated patients at EoT (Figure 3a) to
maintain Hgb in the target range of 9.5–11.5 g/dl (Figure 3c)
(P= 0.045).
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Iron was reliably delivered via dialysate in the FPC group
as evidenced by the consistent increases in serum iron levels
and TSAT from before to after dialysis. The decline in
unsaturated iron binding capacity concomitant with the rise
in serum iron and TSAT indicates that FPC iron is rapidly
donated to transferrin (Figure 2a). After dialysis, FPC iron
was cleared rapidly from the circulation as indicated by
maintenance of predialysis serum iron at baseline levels
(Figure 2b). This is consistent with previous studies showing
an apparent half-life of 1.1–2.2 h and a return of serum iron
to baseline levels by the next dialysis.10 The dialytic rise in
serum iron increases the proportion of diferric transferrin and
efficiency of iron delivery to the erythron because the diferric
molecule has a higher affinity for the transferrin receptor and
carries twice as much iron as the monoferric form.12 A
dialysate FPC dose of 2 μmol/l delivers ∼ 5–7 mg of iron
during the course of each dialysis treatment, thereby replacing
the ongoing iron losses and maintaining iron sufficiency as
reflected by maintenance of reticulocyte hemoglobin, a
marker of iron delivery to the erythron (Figure 4), and
ferritin levels (Figure 3c) relative to placebo. Serum ferritin
levels did not increase in the FPC group (Figure 3c),
indicating that FPC does not increase body iron stores
despite being administered at each hemodialysis session.
Markers of inflammation and oxidative stress showed no
increase in the FPC group relative to placebo.
The PRIME study included patients who were initially iron
replete (baseline ferritin, 200–1000 μg/l). Consequently, i.v.
iron could be withheld until iron deficiency developed, as
indicated by serum ferritin of 200 μg/l. Approximately twice
as many placebo-treated patients as FPC-treated patients
received i.v. iron (20 vs. 11), and placebo-treated patients
received approximately twice as much i.v. iron during the
study (total, 7304 vs. 3790 mg; Figure 3b).
Overall, the findings in the PRIME study indicate that FPC
can effectively deliver iron and maintain Hgb levels without
increasing iron stores while significantly reducing the need for
ESAs (Figure 3a). The ESA requirement of the FPC group
progressively decreased from 6 months forward relative to the
placebo group (Figure 3a), suggesting that the 9-month study
duration likely captured a partial effect of the potential of FPC
to reduce ESA use. The ESA-sparing benefit of FPC is likely
related to its direct donation of iron to transferrin with every
hemodialysis treatment, allowing it to overcome the hepcidin-
induced RE-block and functional iron deficiency that occur
with uremic inflammation. The rapid and direct binding of
FPC iron to transferrin is in contrast to i.v. iron where the
iron-carbohydrate complexes undergo uptake by the RE
system because of their particulate nature and are subject to
sequestration in states of inflammation. The carbohydrate
moiety of i.v. iron may also be responsible for the risk of
hypersensitivity reactions. The higher ESA use in the placebo
group is unlikely to be the result of iron depletion because the
average EoT serum ferritin level was ∼ 450 μg/l in the placebo
group, indicative of sufficient iron stores in the liver.13
Furthermore, studies have demonstrated that in hemodialysis
patient populations with serum ferritin of 300–400 μg/l, more
permissive use of i.v. iron that leads to further increase in
serum ferritin may not always increase Hgb or reduce ESA
%
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use.14,15 The ESA ‘sparing’ effect of i.v. iron in hemodialysis
patients may result from progressively reducing the fraction
of subjects in the population with functional iron deficiency
as the RE system is overloaded with iron.
The nature and frequency of TEAEs and serious TEAEs
were similar in the FPC and placebo groups and consistent
with those expected in hemodialysis patients. In particular, no
hypersensitivity reactions to study drug or increase in the
frequency or severity of infections, cardiac events, or
intradialytic hypotension was observed in the FPC group.
The increased incidence of cough and bradycardia in the FPC
group was not attributed to FPC by the investigators and has
not been observed in any other FPC trials. The mortality rate
was similar in the FPC and placebo groups.
Regular administration of FPC did not worsen the under-
lying concomitant inflammatory state present in uremic
patients as demonstrated by the lack of change in C-reactive
protein, interleukin-6, and malondialdehyde levels, relative
to placebo, over the study period. This may be related
to pyrophosphate binding the iron(III) in FPC tightly in the
circulation while promoting iron transfer rapidly and
specifically to transferrin.11,16 Furthermore, pyrophosphate
is known to be an antioxidant.17
In conclusion, FPC delivered via the hemodialysate
regularly with every hemodialysis treatment is a novel
maintenance iron therapy that can maintain Hgb levels while
reducing ESA use, without overloading iron stores in CKD
5HD patients.
MATERIALS AND METHODS
The PRIME study was conducted at 23 study locations in the United
States from January 2011 to January 2013. The study was approved
by an institutional review board at each site, and written informed
consent was obtained from all patients or an authorized representa-
tive. The study was designed and conducted by the sponsor
(Rockwell Medical, Wixom, MI) in collaboration with the principal
investigators. All authors had full access to the data, reviewed and
edited the manuscript, and assume responsibility for the integrity of
the data.
Study population
Patients ⩾ 18 years old who had received chronic maintenance
hemodialysis for ⩾ 4 months and were currently using an arteriovenous
fistula or graft were enrolled. At screening, patients were required to be
adequately dialyzed (Kt/V41.2) and to have stable ESA doses, Hgb of
9.5–12.0 g/dl, serum ferritin of 200–1000 μg/l, and TSAT of 15–40%.
Exclusion criteria included concomitant infection or active inflamma-
tory disorder, use of 4600mg i.v. iron ⩽ 6 weeks before randomiza-
tion, changes in ESA dose ⩽ 4 weeks before randomization, blood
transfusion ⩽ 12 weeks before randomization, active bleeding, chronic
active hepatitis, or scheduled surgery. Patients with chronic hepatitis
who had hepatic transaminases o2 times the upper limit of normal
were not excluded.
Study methods and interventions
This was a 9-month, prospective, randomized, double-blind,
placebo-controlled, multicenter clinical trial (see ‘Randomization,
Blinding, Sample Size, and Study Assessments’ in Supplementary
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Appendix online). The study was exploratory and was not pros-
pectively powered to demonstrate ESA sparing by FPC. A post hoc
power calculation demonstrated the study had the ability to detect a
20% difference between groups with 80% power.
Patients were randomized in a 1:1 ratio to receive dialysate containing
FPC (2 μmol/l (110 μg/l) iron) or standard dialysate (placebo) at every
dialysis session. Randomization was stratified by baseline ESA dose. The
blind was maintained by providing the study drug in containers with
premixed FPC or placebo liquid bicarbonate concentrates.
The study comprised a 2-week screening period, a 36-week
treatment period, and a 1-week follow-up period. Predialysis Hgb
was measured weekly; serum iron, ferritin, and TSAT were measured
every other week. Postdialysis serum iron, unsaturated iron binding
capacity, transferrin, and calculated TSAT were assessed every
4 weeks through week 12 and then every 12 weeks.
Intravenous iron and changes in ESA dose, type, and adminis-
tration route were prohibited during weeks 1 through 4, except for
ESA dose reductions that were required to manage high Hgb levels.
Beginning at week 5, i.v. iron could be administered and the ESA
dose could be administered or adjusted to maintain Hgb from 9.5 to
11.5 g/dl. An independent, blinded, central anemia management
center facilitated adherence to protocol-specified anemia manage-
ment (see ‘Iron Management and Monitoring of Iron Status’ and
Tables S5 and S6 in Supplementary Appendix online). Study drug
was withheld and replaced by the standard bicarbonate used in the
dialysis center if patients had a systemic infection requiring
administration of antibiotics (see ‘Criteria and Procedures for
Study Drug Withholding’ in Supplementary Appendix online).
Study drug was resumed after discontinuation of antibiotics.
Safety monitoring included monthly analysis of laboratory
parameters and close monitoring of patients during dialysis for
symptoms and signs of potential iron toxicity (see Supplementary
Table S4 online; protocol is available at the journal website).
Outcomes
The primary efficacy outcome was the percentage change from
baseline to EoT in the ESA dose required to maintain Hgb in the
Table 2 | Frequency of treatment-emergent adverse events by system organ class
FPC (n=54) Placebo (n=49)
MedDRA system organ classa Events, n Patients, n (%) Events, n Patients, n (%)
Any TEAE 559 50 (92.6) 651 46 (93.9)
Blood and lymphatic system disorders 6 4 (7.4) 2 2 (4.1)
Cardiac disorders 28 14 (25.9) 37 13 (26.5)
Ear and labyrinth disorders 1 1 (1.9) 2 2 (4.1)
Endocrine disorders 2 2 (3.7) 1 1 (2.0)
Eye disorders 3 2 (3.7) 7 4 (8.2)
Gastrointestinal disorders 57 28 (51.9) 75 27 (55.1)
General disorders and administration site conditions 32 19 (35.2) 24 18 (36.7)
Immune system disorders 1 1 (1.9) 4 3 (6.1)
Infections and infestations 34 21 (38.9) 31 24 (49.0)
Injury, poisoning, and procedural complications 219 35 (64.8) 267 33 (67.3)
Investigations 9 7 (13.0) 14 10 (20.4)
Metabolism and nutrition disorders 26 17 (31.5) 26 20 (40.8)
Musculoskeletal and connective tissue disorders 33 14 (25.9) 51 17 (34.7)
Neoplasms benign, malignant, and unspecified (including cysts and polyps) 3 2 (3.7) 1 1 (2.0)
Nervous system disorders 36 14 (25.9) 40 20 (40.8)
Psychiatric disorders 9 6 (11.1) 9 7 (14.3)
Renal and urinary disorders 1 1 (1.9) 2 2 (4.1)
Reproductive system and breast disorders 0 0 (0.0) 1 1 (2.0)
Respiratory, thoracic, and mediastinal disorders 37 19 (35.2) 32 15 (30.6)
Skin and subcutaneous tissue disorders 8 6 (11.1) 12 9 (18.4)
Vascular disorders 14 13 (24.1) 13 10 (20.4)
Abbreviations: FPC, ferric pyrophosphate citrate; TEAE, treatment-emergent adverse event.
aVerbatim terms were coded using the Medical Dictionary for Regulatory Activities (MedDRA), version 14.1. Patients who experienced more than one event within a System
Organ Class are counted only once in that System Organ Class.
Table 3 | Treatment-emergent adverse events reported in
410% of patients in either group
FPC, n=54 Placebo, n=49
Preferred terma
Events,
n
Patients,
n (%)
Events,
n
Patients,
n (%)
Any event 559 50 (92.6) 651 46 (93.9)
Procedural hypotension 145 18 (33.3) 184 20 (40.8)
Hemodialysis-induced symptom 19 12 (22.2) 13 6 (12.2)
Cough 15 12 (22.2) 3 3 (6.1)
Diarrhea 14 10 (18.5) 17 8 (16.3)
Nausea 12 8 (14.8) 11 7 (14.3)
Fluid overload 9 8 (14.8) 6 6 (12.2)
Dyspnea 9 8 (14.8) 11 5 (10.2)
Headache 16 7 (13.0) 16 8 (16.3)
Asthenia 11 7 (13.0) 3 3 (6.1)
Bradycardia 15 7 (13.0) 3 2 (4.1)
Vomiting 7 6 (11.1) 10 8 (16.3)
Upper respiratory tract infection 8 6 (11.1) 4 4 (8.2)
Arteriovenous fistula site
complication
7 4 (7.4) 17 10 (20.4)
Pain in extremity 4 4 (7.4) 10 9 (18.4)
Dizziness 9 4 (7.4) 6 5 (10.2)
Muscle spasms 12 3 (5.6) 15 5 (10.2)
Pyrexia 4 3 (5.6) 5 5 (10.2)
Arthralgia 2 2 (3.7) 7 6 (12.2)
Hypersensitivity/anaphylaxisb 0 — 0 —
Abbreviation: FPC, ferric pyrophosphate citrate.
aVerbatim terms were coded using the Medical Dictionary for Regulatory Activities
(MedDRA), version 14.1. Patients who experienced the same event more than once
are counted only once for that event.
bNo events related to study drug were reported.
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target range, adjusted for baseline Hgb. All ESA doses were converted
to standard epoetin units. The key secondary outcomes included the
amount of supplementary i.v. iron. Exploratory analyses included
predialysis measurement of markers of inflammation and oxidative
stress at weeks 1 and 36.
Safety and tolerability were determined by the incidence and
severity of TEAEs, and clinically significant changes in physical
examinations, vital sign measurements, and laboratory tests. Iron
parameters were assessed for comparison of predialysis with
postdialysis serum iron and unsaturated iron binding capacity and
baseline to EoT predialysis ferritin levels between groups.
Statistical analysis
Statistical comparisons were performed using two-sided tests at the
α= 0.05 significance level. Results were not adjusted for multiple
comparisons.
The modified intent-to-treat population (randomized patients
who received ⩾ 1 dose of study drug and had any postbaseline ESA
dose information) was used for the efficacy analyses. Safety analyses
were conducted using the safety analysis population (all randomized
patients who received study drug).
Primary end point analysis was the percentage change in
prescribed ESA dose from baseline to EoT (average of last 2 weeks
of randomized treatment), performed using a one-way analysis of
covariance model with percentage change from baseline in ESA as
the response variable, treatment as the factor, and baseline Hgb as a
covariate. Continuous variable secondary end points were summar-
ized descriptively and analyzed using Wilcoxon rank-sum tests.
The number and percentage of patients with TEAEs were
summarized. Intradialytic hypotension and hypersensitivity reactions
were summarized by group and 4-week intervals.
All analyses were produced using SAS statistical software version
9.1.3 or higher (SAS Institute, Cary, NC).
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